Physician profile
Jay C Tyroler
NPI 1962544700
$11,431.49
in general payments reported to CMS, 2019-2025
43 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,667 · 2020: $1,546 · 2021: $1,824 · 2022: $1,537 · 2023: $1,934 · 2024: $1,448 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,816 · Education: $41.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,815.50 |
| Education | $41.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,652.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,611.05 | 2019-2025 | |
| Abbvie INC. | $1,074.73 | 2019-2025 | Synthroid, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $841.64 | 2019-2025 | Jardiance, Tradjenta |
| Amgen INC. | $744.51 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $649.50 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Janssen Pharmaceuticals, INC | $613.99 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $578.62 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $438.89 | 2019-2023 | |
| Allergan, INC. | $365.81 | 2019-2020 | |
| Bausch Health US, LLC | $294.06 | 2021-2025 | Aplenzin |
| Exact Sciences Corporation | $232.59 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $212.01 | 2019-2025 | Capvaxive, M-M-R II |
| Esperion Therapeutics, INC. | $184.60 | 2021-2022 | |
| Abbott Laboratories | $180.62 | 2019-2024 | Freestyle Libre 3, Freestyle Libre, Proclaim |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Tyroler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.